I saw on Pharmacompass that Mylan and Teva had an exclusivity period on this which expired on 2nd June. So Alembic is a late entrant in the game. This was not the case in Abilify, which was a day 1 launch. So it may be difficult to take market share. What do you think?
Other players are
Teva
Mylan
Lupin
Apotex
Watson
Looks like Lupin has already been exporting to US
| Subscribe To Our Free Newsletter |
